Komori
M&A and Subsidiary Changes4559ZERIA PHARMACEUTICAL CO.,LTD.Pharmaceuticals

(Correction) Partial correction to the “Notice concerning the acquisition of an equity interest in Haupt Pharma Wulfling GmbH by a consolidated subsidiary of the Company (making it a sub-subsidiary)” and the “Summary of Financial Results for the Interim Period of the Fiscal Year Ending March 2027”

The alphabetic spelling of the name of the target company in the M&A disclosure dated 26 October 2026 and the Interim Financial Results Summary dated 4 November 2026 was changed from “Haupt Pharma Wülfling GmbH” to “Haupt Pharma Wülfing GmbH.” No numerical data was changed.

Worth reading
41Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

What was corrected and how

A subsequent correction by the company to the contents of an already published filing.

Original disclosure26 October 2026, 4 November 2026

“Notice concerning the acquisition of an equity interest in Haupt Pharma Wülfling GmbH by a consolidated subsidiary of the Company (making it a sub-subsidiary)” and “Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)”

Open the original document
21 daysThe pre-correction wording stayed published for this period (Calculated from the Original Disclosure Date Indicated in the Document)
This correction2026-11-16
Location of correction (where in the original document)

The 【Title】, 【opening of the main text (preamble)】 and 【3. Overview of the sub-subsidiary to be transferred (HPW), (1) Name】 of the “Notice concerning the acquisition of an equity interest in Haupt Pharma Wülfling GmbH by a consolidated subsidiary of the Company (making it a sub-subsidiary),” and 【page 11 of the attached materials】 (notes on significant subsequent events) of the “Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)”

Before correction

Haupt Pharma Wülfling GmbH

After correction

Haupt Pharma Wülfing GmbH

ChangesCorrected from Haupt Pharma Wülfling GmbH to Haupt Pharma Wülfing GmbH
Impact on Business Performance (the company’s explanation)

There are no corrections to the numerical data.

Reason for correction

Because the alphabetic spelling of the corporate name of the company subject to the equity interest acquisition was incorrect.

What was corrected and how
ItemDetails
Disclosure subject to correction“Notice concerning the acquisition of an equity interest in Haupt Pharma Wülfling GmbH by a consolidated subsidiary of the Company (making it a sub-subsidiary)” and “Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)”
Original disclosure date26 October 2026, 4 November 2026
Location of correctionThe 【Title】, 【opening of the main text (preamble)】 and 【3. Overview of the sub-subsidiary to be transferred (HPW), (1) Name】 of the “Notice concerning the acquisition of an equity interest in Haupt Pharma Wülfling GmbH by a consolidated subsidiary of the Company (making it a sub-subsidiary),” and 【page 11 of the attached materials】 (notes on significant subsequent events) of the “Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)”
Details of correctionHaupt Pharma Wülfling GmbH → Haupt Pharma Wülfing GmbH
Reason for correctionBecause the alphabetic spelling of the corporate name of the company subject to the equity interest acquisition was incorrect.
Impact on Business PerformanceThere are no corrections to the numerical data.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Because the alphabetic spelling of the corporate name of the company subject to the equity interest acquisition was incorrect.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
(Correction) Partial correction to the “Notice concerning the acquisition of an equity interest in Haupt Pharma Wulfling GmbH by a consolidated subsidiary of the Company (making it a sub-subsidiary)” and the “Summary of Financial Results for the Interim Period of the Fiscal Year Ending March 2027” | ZERIA PHARMACEUTICAL CO.,LTD. (4559) timely disclosure | Komori